Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 133Squamous Cell Carcinoma of Head and Neck 76Lung Neoplasms 49Head and Neck Neoplasms 45Urinary Bladder Neoplasms 43Parkinson Disease 4, Autosomal Dominant Lewy Body 33Oropharyngeal Neoplasms 32Nasopharyngeal Carcinoma 32Biliary Tract Neoplasms 31Uterine Cervical Neoplasms 30Cholangiocarcinoma 28Esophageal Squamous Cell Carcinoma 26Carcinoma 24Neoplasms 23Ovarian Neoplasms 22Neoplasm Metastasis 22Small Cell Lung Carcinoma 21Carcinoma, Squamous Cell 20Stomach Neoplasms 18Colorectal Neoplasms 18Carcinoma, Transitional Cell 17Pancreatic Neoplasms 16Esophageal Neoplasms 16Mesothelioma, Malignant 15Gallbladder Neoplasms 15Mouth Neoplasms 14Laryngeal Neoplasms 13Hypopharyngeal Neoplasms 12Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10

Interventions

Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Radiosurgery 2Liver Transplantation 2Gemcitabine 2Cisplatin 2Biopsy 2tislelizumab 1sacituzumab govitecan 1gemcitabine-oxaliplatin regimen 1fludarabine 1dehydroftorafur 1binimetinib 1Tegafur 1S 1 (combination) 1Pancreatic Hormones 1Leucovorin 1Hydroxychloroquine 1Cyclophosphamide 1Cholangiopancreatography, Endoscopic Retrograde 1Capecitabine 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Klatskin Tumor × Cisplatin × 1 year × Clear all
NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡